InMed Announces Appointment of Eric A. Adams as CEO, President and Director

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 16, 2016) - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies, is pleased to announce today the appointment of Mr. Eric A. Adams as CEO, President and as a member of the Board of Directors. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years' experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Mr. Adams states, "I'm excited to join InMed at this stage of its development. The assets developed to date by Dr. Sazzad Hossain, InMed's Chief Scientific Officer, and his research collaborators have significant potential for success. InMed's proprietary bioinformatics drug candidate database, its cutting edge cannabinoid biosynthesis program, and active drug development programs in epidermolysis bullosa, glaucoma and other promising disease targets provide an incredibly strong platform for the company's growth through both direct and licensed revenue models; there are short- and medium-term value driving milestones for InMed in all of these areas. We plan to monetize these assets and continue to fund development of important cannabinoid-based drugs for diseases with high unmet medical needs. I look forward to working with the management team and Board to build a successful, diversified drug development company that will tap into the vast potential of cannabinoid therapeutics and contribute to the understanding and commercialization of this important and largely undiscovered class of drugs."

Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs. He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Chris Bogart will be stepping down as Interim CEO and resuming his role as SVP of Corporate Strategy and Investor Relations. Additionally, InMed announces it has accepted the resignation of Paul Brennen as a Director of the Company, effective today. The Board wishes to thank Mr. Brennan for his efforts.

About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics drug candidate identification platform, biosynthesis manufacturing, and accelerated drug development pathway are the fundamental value drivers of the company.

For more information, visit www.inmedpharma.com

Cautionary Note Regarding Forward-Looking Information

Forward-Looking Statements

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.